JP2020535176A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535176A5 JP2020535176A5 JP2020517586A JP2020517586A JP2020535176A5 JP 2020535176 A5 JP2020535176 A5 JP 2020535176A5 JP 2020517586 A JP2020517586 A JP 2020517586A JP 2020517586 A JP2020517586 A JP 2020517586A JP 2020535176 A5 JP2020535176 A5 JP 2020535176A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- polymer
- composition according
- polymer matrix
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 48
- 229920000642 polymer Polymers 0.000 claims description 42
- 239000011159 matrix material Substances 0.000 claims description 28
- 239000004480 active ingredient Substances 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 15
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 10
- 150000004676 glycans Chemical class 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 229920001577 copolymer Polymers 0.000 claims description 6
- 229960003529 diazepam Drugs 0.000 claims description 6
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical group CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 3
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 3
- 229960004538 alprazolam Drugs 0.000 claims description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 3
- 229960005139 epinephrine Drugs 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 241000416162 Astragalus gummifer Species 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 240000007472 Leucaena leucocephala Species 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000017531 blood circulation Effects 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000000412 dendrimer Substances 0.000 claims description 2
- 229920000736 dendritic polymer Polymers 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000010408 film Substances 0.000 claims description 2
- 238000011010 flushing procedure Methods 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229940124549 vasodilator Drugs 0.000 claims description 2
- 239000003071 vasodilator agent Substances 0.000 claims description 2
- 229920003169 water-soluble polymer Polymers 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 2
- 229930013930 alkaloid Natural products 0.000 claims 1
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 9
- 108060003345 Adrenergic Receptor Proteins 0.000 description 8
- 102000017910 Adrenergic receptor Human genes 0.000 description 8
- 239000000419 plant extract Substances 0.000 description 7
- 229930015704 phenylpropanoid Natural products 0.000 description 5
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 244000061408 Eugenia caryophyllata Species 0.000 description 4
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 239000003961 penetration enhancing agent Substances 0.000 description 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- SCCDQYPEOIRVGX-UHFFFAOYSA-N Acetyleugenol Chemical compound COC1=CC(CC=C)=CC=C1OC(C)=O SCCDQYPEOIRVGX-UHFFFAOYSA-N 0.000 description 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 2
- 239000005770 Eugenol Substances 0.000 description 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 2
- RGIBXDHONMXTLI-UHFFFAOYSA-N chavicol Chemical compound OC1=CC=C(CC=C)C=C1 RGIBXDHONMXTLI-UHFFFAOYSA-N 0.000 description 2
- 229930016911 cinnamic acid Natural products 0.000 description 2
- 235000013985 cinnamic acid Nutrition 0.000 description 2
- 229960002217 eugenol Drugs 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- ZMQAAUBTXCXRIC-UHFFFAOYSA-N safrole Chemical compound C=CCC1=CC=C2OCOC2=C1 ZMQAAUBTXCXRIC-UHFFFAOYSA-N 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- IAZKGRRJAULWNS-UHFFFAOYSA-N Chavicol Natural products OC1=CC=C(CCC=C)C=C1 IAZKGRRJAULWNS-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000006199 Parasomnias Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229930014594 aporphine alkaloid Natural products 0.000 description 1
- 150000008441 aporphines Chemical class 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- -1 cinnamic acid ester Chemical class 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023188095A JP2024012484A (ja) | 2017-09-27 | 2023-11-02 | 増強された透過を有する医薬組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201715717856A | 2017-09-27 | 2017-09-27 | |
| US15/717,856 | 2017-09-27 | ||
| US15/724,234 | 2017-10-03 | ||
| US15/724,234 US11273131B2 (en) | 2016-05-05 | 2017-10-03 | Pharmaceutical compositions with enhanced permeation |
| US201862735822P | 2018-09-24 | 2018-09-24 | |
| US62/735,822 | 2018-09-24 | ||
| PCT/US2018/053026 WO2019067667A1 (en) | 2017-09-27 | 2018-09-27 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023188095A Division JP2024012484A (ja) | 2017-09-27 | 2023-11-02 | 増強された透過を有する医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020535176A JP2020535176A (ja) | 2020-12-03 |
| JP2020535176A5 true JP2020535176A5 (enExample) | 2021-11-11 |
| JP7431724B2 JP7431724B2 (ja) | 2024-02-15 |
Family
ID=63858167
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517586A Active JP7431724B2 (ja) | 2017-09-27 | 2018-09-27 | 増強された透過を有する医薬組成物 |
| JP2023188095A Pending JP2024012484A (ja) | 2017-09-27 | 2023-11-02 | 増強された透過を有する医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023188095A Pending JP2024012484A (ja) | 2017-09-27 | 2023-11-02 | 増強された透過を有する医薬組成物 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3687509A1 (enExample) |
| JP (2) | JP7431724B2 (enExample) |
| KR (2) | KR102845228B1 (enExample) |
| CN (1) | CN111132670A (enExample) |
| BR (1) | BR112020005967A2 (enExample) |
| CA (1) | CA3076815A1 (enExample) |
| IL (2) | IL321263A (enExample) |
| WO (1) | WO2019067667A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| KR20230137362A (ko) | 2016-05-05 | 2023-10-04 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 강화된 전달 에프네프린 조성물 |
| AU2020373100A1 (en) * | 2019-11-01 | 2022-05-19 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
| CA3160750A1 (en) | 2019-12-09 | 2021-06-17 | Anthony Richard Gerardi | Oral product comprising a cannabinoid |
| DE102020122557A1 (de) * | 2020-08-28 | 2022-03-03 | Lts Lohmann Therapie-Systeme Ag | Mucosa-Perforierung |
| US11839602B2 (en) | 2020-11-25 | 2023-12-12 | Nicoventures Trading Limited | Oral cannabinoid product with lipid component |
| WO2023076281A1 (en) | 2021-10-25 | 2023-05-04 | Aquestive Therapeutics, Inc. | Oral and nasal compositions and methods of treatment |
| CN114894675B (zh) * | 2022-05-06 | 2024-04-19 | 江苏省农业科学院 | 一种农药助剂在植物叶片表面渗透行为的比较方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE183926T1 (de) * | 1993-09-29 | 1999-09-15 | Alza Corp | Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern |
| US20050042271A1 (en) * | 1999-11-19 | 2005-02-24 | Xel Herbaceuticals, Inc . | Transdermal delivery system for alkaloids of aconitum species |
| ATE485837T1 (de) * | 2000-08-03 | 2010-11-15 | Antares Pharma Ipl Ag | Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert |
| US7425292B2 (en) | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| JP2004043450A (ja) * | 2002-05-16 | 2004-02-12 | Kyukyu Yakuhin Kogyo Kk | 速溶性フィルム状製剤 |
| JP2004131495A (ja) * | 2002-09-17 | 2004-04-30 | Nippon Boehringer Ingelheim Co Ltd | 非ステロイド系抗炎症剤の局所送達用医薬組成物 |
| US20040127531A1 (en) * | 2002-11-21 | 2004-07-01 | Lu Guang Wei | Adhesive coated sheet for dermal delivery of a selective cyclooxygenase-2 inhibitor |
| MY141815A (en) * | 2003-04-30 | 2010-06-30 | Purdue Pharma Lp | Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer |
| BR0302017B1 (pt) * | 2003-06-02 | 2014-10-29 | Ems Sigma Pharma Ltda | Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos |
| RU2354354C2 (ru) * | 2003-06-17 | 2009-05-10 | СК Холдингз., Ко., Лтд. | Трансназальные микроэмульсии, содержащие диазепам |
| US20050266085A1 (en) * | 2004-05-28 | 2005-12-01 | Warner Kevin S | Gelled emulsion and microemulsion formulations for dermal drug delivery |
| IL175338A0 (en) * | 2006-05-01 | 2006-09-05 | Biota Ltd | Orally administrable films and preparation thereof |
| US9125836B2 (en) * | 2007-06-07 | 2015-09-08 | Sato Pharmaceutical Co., Ltd. | Film preparation with rapidly dissolving property and flexibility |
| JP5435853B2 (ja) * | 2007-09-28 | 2014-03-05 | 興和株式会社 | 塩酸フェニレフリン含有速溶性フィルム製剤及びその製造方法 |
| WO2013063614A1 (en) * | 2011-10-28 | 2013-05-02 | Sung-Yun Kwon | Dissolving solid solution perforator patch for migraine treatment |
| NZ706302A (en) * | 2012-10-11 | 2017-07-28 | Ix Biopharma Ltd | Sublingual wafer solid dosage form containing amylopectin |
| CA2919442A1 (en) * | 2013-07-31 | 2015-02-05 | Intelgenx Corp. | Instantly wettable oral film dosage form without surfactant or polyalcohol |
| CA2993999C (en) * | 2015-08-05 | 2023-07-25 | University Of Rochester | Antimicrobial compositions comprising mupirocin and neomycin |
| WO2017192923A1 (en) * | 2016-05-05 | 2017-11-09 | Monosol Rx, Llc | Pharmaceutical compositions with enhanced permeation |
| KR20230137362A (ko) * | 2016-05-05 | 2023-10-04 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 강화된 전달 에프네프린 조성물 |
| CN105902524A (zh) * | 2016-06-30 | 2016-08-31 | 合肥华方医药科技有限公司 | 一种酒石酸唑吡坦舌下膜及其制备方法 |
-
2018
- 2018-09-27 CA CA3076815A patent/CA3076815A1/en active Pending
- 2018-09-27 BR BR112020005967-6A patent/BR112020005967A2/pt unknown
- 2018-09-27 JP JP2020517586A patent/JP7431724B2/ja active Active
- 2018-09-27 WO PCT/US2018/053026 patent/WO2019067667A1/en not_active Ceased
- 2018-09-27 KR KR1020207012033A patent/KR102845228B1/ko active Active
- 2018-09-27 CN CN201880062717.5A patent/CN111132670A/zh active Pending
- 2018-09-27 IL IL321263A patent/IL321263A/en unknown
- 2018-09-27 KR KR1020257026354A patent/KR20250126144A/ko active Pending
- 2018-09-27 EP EP18786591.0A patent/EP3687509A1/en active Pending
-
2020
- 2020-03-22 IL IL273479A patent/IL273479B2/en unknown
-
2023
- 2023-11-02 JP JP2023188095A patent/JP2024012484A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020535176A5 (enExample) | ||
| JP2020535162A5 (enExample) | ||
| JP6770157B2 (ja) | 特定の投薬量の活性物質を皮膚又は粘膜に投与するための電気流体力学的に得られた繊維を含む組成物 | |
| IL273479B1 (en) | Pharmaceutical compositions with enhanced permeation | |
| JP6929916B2 (ja) | 適用部位における滞留時間が改善された、電気流体力学的に得られた繊維を含む医薬組成物 | |
| JP5421511B2 (ja) | 胃に留まるガバペンチン投薬を使用する処置方法 | |
| JP5841151B2 (ja) | 鼻腔噴霧剤 | |
| ES2426963T3 (es) | Preparación en forma de película con sustancias oleosas para la administración oral | |
| JP2019519488A5 (enExample) | ||
| JP2015512945A (ja) | 錠剤と液体または半固体の充填剤とを含む軟質弾性カプセル、ならびにそれらの製造方法 | |
| IL273485B1 (en) | Enhanced delivery epinephrine and prodrug compositions | |
| WO2002003964A1 (fr) | Composition pharmaceutique orale a liberation controlee et a absorption prolongee | |
| NO343482B1 (no) | Vannløselige filmer omfattende lavviskositet alginater | |
| WO2014154029A1 (zh) | 复合骨架材料及其药物组合物 | |
| JP6306573B2 (ja) | ツーピース硬カプセル用の耐酸性バンド溶液 | |
| Garg et al. | Applications of natural polymers in mucoadhesive drug delivery: An overview | |
| CN114667084B (zh) | 非动物性软凝胶胶囊制剂、其制备方法及使用方法 | |
| AU2016293890A1 (en) | Pharmaceutical composition containing celecoxib and tramadol | |
| Kumar et al. | Natural excipients: A review | |
| CN101229225A (zh) | 丹参总酚酸胃滞留制剂 | |
| WO2014137189A1 (ko) | 고함량의 약물을 함유하는 구강 붕해 필름 및 이의 제조방법 | |
| US20130216594A1 (en) | Preparation of orodispersible films | |
| US11083635B2 (en) | Tampon delivery system for a pharmaceutical, holistic or medicinal component | |
| TW200800155A (en) | Gastric retentive gabapentin dosage forms and methods for using same | |
| JPH07507303A (ja) | 非イオン系セルロースエーテル誘導体およびキチン由来の重合体を含む医薬用粉末組成物 |